LivaNova (NASDAQ:LIVN) Sets New 1-Year High – Should You Buy?

LivaNova PLC (NASDAQ:LIVN) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $85.45 and last traded at $85.1840, with a volume of 750889 shares traded. The stock had previously closed at $82.46.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: LivaNova reported second-quarter EPS of $1.26, beating the $1.08 consensus estimate and rising from $1.05 a year earlier. Revenue increased 10.8% year over year to $390.59 million, exceeding expectations of $380.34 million. LivaNova Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised fiscal 2026 adjusted EPS guidance to $4.30-$4.40, above the prior market consensus of $4.15. Growth in the Cardiopulmonary and Epilepsy businesses helped drive margin improvement, supporting the bullish outlook. LivaNova raises guidance on Q2 beats
• Positive Sentiment: Needham raised its price target for LIVN from $81 to $93 and maintained a “Buy” rating, indicating confidence that earnings growth and execution could support further upside. LivaNova price target increase
• Neutral Sentiment: The company’s revenue outlook was approximately $1.5 billion, broadly in line with consensus, so the primary guidance upside came from profitability rather than a material increase in projected sales. LivaNova Q2 earnings and outlook
• Negative Sentiment: LIVN recently traded near its 52-week high and at a relatively elevated valuation, with a P/E ratio near 39. The subsequent decrease suggests investors may be locking in gains or demanding additional upside beyond the strong results and raised outlook.

Analysts Set New Price Targets

A number of research firms have commented on LIVN. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Mizuho increased their price objective on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Needham & Company LLC upped their target price on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays raised their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $83.50.

LivaNova Price Performance

The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The company has a 50-day moving average price of $79.54 and a 200-day moving average price of $70.61. The firm has a market capitalization of $4.16 billion, a P/E ratio of 38.86 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 5th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.18. The firm had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.34 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. On average, sell-side analysts predict that LivaNova PLC will post 3.73 earnings per share for the current year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of LivaNova by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares during the period. Goldman Sachs Group Inc. increased its position in shares of LivaNova by 4.6% during the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after acquiring an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LivaNova by 10.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio acquired a new stake in shares of LivaNova during the first quarter worth $130,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.